An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus
Abstract Background Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal mo...
Saved in:
Published in | Neuro-oncology (Charlottesville, Va.) Vol. 23; no. 11; pp. 1911 - 1921 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
US
Oxford University Press
02.11.2021
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent.
Methods
We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry.
Results
In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS).
Conclusions
This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic. |
---|---|
AbstractList | Abstract
Background
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent.
Methods
We generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry.
Results
In vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS).
Conclusions
This adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic. BACKGROUNDOncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to evaluate the mechanisms of efficacy. However, due to the species selectivity of adenovirus, there is currently no single animal model that supports viral replication, tumor oncolysis, and a virus-mediated immune response. To address this gap, we took advantage of the Syrian hamster to develop the first intracranial glioma model that is both adenovirus replication-permissive and immunocompetent. METHODSWe generated hamster glioma stem-like cells (hamGSCs) by transforming hamster neural stem cells with hTERT, simian virus 40 large T antigen, and h-RasV12. Using a guide-screw system, we generated an intracranial tumor model in the hamster. The efficacy of the oncolytic adenovirus Delta-24-RGD was assessed by survival studies, and tumor-infiltrating lymphocytes (TILs) were evaluated by flow cytometry. RESULTSIn vitro, hamGSCs supported viral replication and were susceptible to Delta-24-RGD mediated cell death. In vivo, hamGSCs consistently developed into highly proliferative tumors resembling high-grade glioma. Flow cytometric analysis of hamster gliomas revealed significantly increased T-cell infiltration in Delta-24-RGD infected tumors, indicative of immune activation. Treating tumor-bearing hamsters with Delta-24-RGD led to significantly increased survival compared to hamsters treated with phosphate buffered saline (PBS). CONCLUSIONSThis adenovirus-permissive, immunocompetent hamster glioma model overcomes the limitations of previous model systems and provides a novel platform to study the interactions between tumor cells, the host immune system, and oncolytic adenoviral therapy; understanding of which will be critical to implementing oncolytic adenovirus in the clinic. |
Author | Phillips, Lynette M Ledbetter, Daniel Gomez-Manzano, Candelaria Lang, Frederick F Parker Kerrigan, Brittany C Fueyo, Juan Singh, Sanjay Daou, Marc Yuan, Ying Gumin, Joy Yang, Jing Li, Shoudong Hossain, Anwar |
AuthorAffiliation | 1 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA 2 The Brain Tumor Center, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA 4 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA |
AuthorAffiliation_xml | – name: 2 The Brain Tumor Center, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA – name: 4 Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA – name: 3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA – name: 1 Department of Neurosurgery, The University of Texas MD Anderson Cancer Center , Houston, Texas , USA |
Author_xml | – sequence: 1 givenname: Lynette M surname: Phillips fullname: Phillips, Lynette M organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 2 givenname: Shoudong surname: Li fullname: Li, Shoudong organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 3 givenname: Joy surname: Gumin fullname: Gumin, Joy organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 4 givenname: Marc surname: Daou fullname: Daou, Marc organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 5 givenname: Daniel surname: Ledbetter fullname: Ledbetter, Daniel organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 6 givenname: Jing surname: Yang fullname: Yang, Jing organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 7 givenname: Sanjay surname: Singh fullname: Singh, Sanjay organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 8 givenname: Brittany C surname: Parker Kerrigan fullname: Parker Kerrigan, Brittany C organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 9 givenname: Anwar surname: Hossain fullname: Hossain, Anwar organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 10 givenname: Ying orcidid: 0000-0003-3163-480X surname: Yuan fullname: Yuan, Ying organization: Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 11 givenname: Candelaria surname: Gomez-Manzano fullname: Gomez-Manzano, Candelaria organization: The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 12 givenname: Juan surname: Fueyo fullname: Fueyo, Juan organization: The Brain Tumor Center, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA – sequence: 13 givenname: Frederick F surname: Lang fullname: Lang, Frederick F email: flang@mdanderson.org organization: Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA |
BookMark | eNqFUctqHDEQFMEm9tq55qxjAtFaj9E8LgHjNxgMTnwWWk3PRkGPiTSzeP8-sncx-ORTN3RVdXfVAh2EGAChr4wuGe3EWYA5BnMWol4x3n5Cx0xyQWRb1wevPSetZM0RWuT8l1LOZM0-oyNRUdl1nB2j5_OArfdzAGKiH2GCMP3ACUZnjZ5sDGSE5G3OdgP41zZZHfCt9nmChNfORq-xjz04PMSEYaPdXFhhjS_BTZrwijzeXOJyYXTbyRqsewhxY9OcT9HhoF2GL_t6gp6ur35f3JL7h5u7i_N7YirKJiLK9U0jWKUpG7qXBzitTbMa-LAyXW9aKQTt-5qaoaXFAwF9Ax2IuoK2G4pDJ-jnTnecVx56U_5L2qkxWa_TVkVt1ftJsH_UOm5UK2shmCwC3_YCKf6bIU-q2GHAOR0gzllxKWTLm6ZqCnS5g5oUc04wvK1hVL3EpXZxqX1chfB9R4jz-BH2PwB6nGc |
CitedBy_id | crossref_primary_10_3390_ijms25095007 crossref_primary_10_3389_fimmu_2023_1126969 crossref_primary_10_3389_fimmu_2023_1060540 crossref_primary_10_1007_s12094_022_02830_x crossref_primary_10_3389_fonc_2024_1423143 |
Cites_doi | 10.1080/2162402X.2017.1358839 10.1007/s11060-017-2395-y 10.1200/JCO.2017.77.3192 10.1158/0008-5472.CAN-17-0468 10.3171/jns.2000.92.2.0326 10.1128/MCB.25.15.6464-6474.2005 10.1093/infdis/jiv203 10.1093/neuonc/noy075 10.1093/brain/aww046 10.1111/imm.12116 10.1038/mt.2009.156 10.1016/j.vetimm.2016.12.003 10.1128/JVI.02184-14 10.1158/1078-0432.CCR-16-0477 10.1371/journal.pone.0097495 10.1093/jnci/djm102 10.1093/jnci/95.9.652 10.1371/journal.pone.0097407 10.1038/nature03128 10.1200/JCO.2017.75.8219 10.1016/B978-0-12-398342-8.00003-3 10.1056/NEJMoa1716435 10.1093/neuonc/now002 10.1158/0008-5472.CAN-05-3497 10.1016/0168-1702(89)90026-9 10.1038/cgt.2014.13 10.1038/mt.2008.162 10.1016/j.cell.2013.09.034 10.1073/pnas.1303607110 10.1038/cgt.2009.6 |
ContentType | Journal Article |
Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021 |
Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021 |
DBID | AAYXX CITATION 7X8 5PM |
DOI | 10.1093/neuonc/noab128 |
DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1523-5866 |
EndPage | 1921 |
ExternalDocumentID | 10_1093_neuonc_noab128 10.1093/neuonc/noab128 |
GrantInformation_xml | – fundername: ; – fundername: ; grantid: CA247970 – fundername: ; grantid: P30CA16672; NCI# CA0166772 |
GroupedDBID | --- .2P .I3 .XZ .ZR 0R~ 123 18M 1TH 29N 2WC 36B 4.4 48X 53G 5VS 5WD 70D AABZA AACZT AAJKP AAJQQ AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABPTD ABQLI ABQNK ABWST ABXVV ABZBJ ACGFO ACGFS ACUFI ACUTO ACYHN ADBBV ADEYI ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC AOIJS APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMB EMOBN ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HYE HZ~ IOX J21 KBUDW KOP KQ8 KSI KSN M49 MHKGH N9A NGC NOMLY NOYVH NU- O0~ O9- OAUYM OAWHX OCZFY ODMLO OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM Q1. Q5Y RD5 RHF ROX RPM RUSNO RW1 RXO SV3 TEORI TJX TR2 UDS W8F WOQ X7H YAYTL YKOAZ YXANX ~91 AAYXX CITATION 7X8 5PM |
ID | FETCH-LOGICAL-c401t-351777314a01f90215206c7bf2fbc9dc85330dd60cf80ab13ed7e9e364e89f093 |
IEDL.DBID | RPM |
ISSN | 1522-8517 |
IngestDate | Tue Sep 17 21:24:01 EDT 2024 Fri Aug 16 20:54:08 EDT 2024 Fri Aug 23 01:43:15 EDT 2024 Wed Aug 28 03:17:10 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Keywords | immune-competent model glioma oncolytic adenovirus |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c401t-351777314a01f90215206c7bf2fbc9dc85330dd60cf80ab13ed7e9e364e89f093 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-3163-480X |
OpenAccessLink | https://academic.oup.com/neuro-oncology/article-pdf/23/11/1911/41064117/noab128.pdf |
PMID | 34059921 |
PQID | 2535827747 |
PQPubID | 23479 |
PageCount | 11 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8563315 proquest_miscellaneous_2535827747 crossref_primary_10_1093_neuonc_noab128 oup_primary_10_1093_neuonc_noab128 |
PublicationCentury | 2000 |
PublicationDate | 20211102 |
PublicationDateYYYYMMDD | 2021-11-02 |
PublicationDate_xml | – month: 11 year: 2021 text: 20211102 day: 02 |
PublicationDecade | 2020 |
PublicationPlace | US |
PublicationPlace_xml | – name: US |
PublicationTitle | Neuro-oncology (Charlottesville, Va.) |
PublicationYear | 2021 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
References | Boehm (2021110300462725700_CIT0018) 2005; 25 Forsyth (2021110300462725700_CIT0006) 2018; 36 Cloughesy (2021110300462725700_CIT0002) 2018; 20 Lal (2021110300462725700_CIT0014) 2000; 92 Dhar (2021110300462725700_CIT0016) 2009; 17 Brennan (2021110300462725700_CIT0019) 2013; 155 Crosby (2021110300462725700_CIT0015) 2015; 89 Li (2021110300462725700_CIT0029) 2017; 23 Pitter (2021110300462725700_CIT0031) 2016; 139 Jiang (2021110300462725700_CIT0008) 2014; 9 Killela (2021110300462725700_CIT0020) 2013; 110 Chitadze (2021110300462725700_CIT0025) 2017; 6 Lang (2021110300462725700_CIT0005) 2018; 36 Jiang (2021110300462725700_CIT0007) 2007; 99 Mason (2021110300462725700_CIT0026) 2017; 132 Blair (2021110300462725700_CIT0009) 1989; 14 Jiang (2021110300462725700_CIT0022) 2017; 77 Dhar (2021110300462725700_CIT0027) 2014; 21 Singh (2021110300462725700_CIT0021) 2004; 432 Kleijn (2021110300462725700_CIT0030) 2014; 9 Thomas (2021110300462725700_CIT0028) 2008; 16 Desjardins (2021110300462725700_CIT0001) 2018; 379 Rees (2021110300462725700_CIT0024) 2017; 183 Ying (2021110300462725700_CIT0010) 2009; 16 Pino (2021110300462725700_CIT0017) 2011 Thomas (2021110300462725700_CIT0013) 2006; 66 Wold (2021110300462725700_CIT0023) 2012; 115 Wheeler (2021110300462725700_CIT0003) 2016; 18 Prescott (2021110300462725700_CIT0011) 2015; 212 Fueyo (2021110300462725700_CIT0004) 2003; 95 Prescott (2021110300462725700_CIT0012) 2013; 140 |
References_xml | – volume: 6 start-page: e1358839 issue: 11 year: 2017 ident: 2021110300462725700_CIT0025 article-title: In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment publication-title: Oncoimmunology. doi: 10.1080/2162402X.2017.1358839 contributor: fullname: Chitadze – volume: 132 start-page: 463 issue: 3 year: 2017 ident: 2021110300462725700_CIT0026 article-title: Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival publication-title: J Neurooncol. doi: 10.1007/s11060-017-2395-y contributor: fullname: Mason – volume: 36 start-page: 1440 issue: 14 year: 2018 ident: 2021110300462725700_CIT0006 article-title: Oncolytic Virotherapy for Malignant Gliomas publication-title: J Clin Oncol. doi: 10.1200/JCO.2017.77.3192 contributor: fullname: Forsyth – volume: 77 start-page: 3894 issue: 14 year: 2017 ident: 2021110300462725700_CIT0022 article-title: Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-17-0468 contributor: fullname: Jiang – volume: 92 start-page: 326 issue: 2 year: 2000 ident: 2021110300462725700_CIT0014 article-title: An implantable guide-screw system for brain tumor studies in small animals publication-title: J Neurosurg. doi: 10.3171/jns.2000.92.2.0326 contributor: fullname: Lal – volume: 25 start-page: 6464 issue: 15 year: 2005 ident: 2021110300462725700_CIT0018 article-title: Transformation of human and murine fibroblasts without viral oncoproteins publication-title: Mol Cell Biol. doi: 10.1128/MCB.25.15.6464-6474.2005 contributor: fullname: Boehm – volume: 212 start-page: S271 year: 2015 ident: 2021110300462725700_CIT0011 article-title: Natural Immunity to Ebola Virus in the Syrian Hamster Requires Antibody Responses publication-title: J Infect Dis. doi: 10.1093/infdis/jiv203 contributor: fullname: Prescott – volume: 20 start-page: 1383 issue: 10 year: 2018 ident: 2021110300462725700_CIT0002 article-title: Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC publication-title: Neuro Oncol. doi: 10.1093/neuonc/noy075 contributor: fullname: Cloughesy – volume: 139 start-page: 1458 issue: Pt 5 year: 2016 ident: 2021110300462725700_CIT0031 article-title: Corticosteroids compromise survival in glioblastoma publication-title: Brain. doi: 10.1093/brain/aww046 contributor: fullname: Pitter – volume: 140 start-page: 168 issue: 2 year: 2013 ident: 2021110300462725700_CIT0012 article-title: The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster publication-title: Immunology. doi: 10.1111/imm.12116 contributor: fullname: Prescott – volume: 17 start-page: 1724 issue: 10 year: 2009 ident: 2021110300462725700_CIT0016 article-title: Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model publication-title: Mol Ther. doi: 10.1038/mt.2009.156 contributor: fullname: Dhar – volume: 183 start-page: 40 year: 2017 ident: 2021110300462725700_CIT0024 article-title: Characterisation of monoclonal antibodies specific for hamster leukocyte differentiation molecules publication-title: Vet Immunol Immunopathol. doi: 10.1016/j.vetimm.2016.12.003 contributor: fullname: Rees – volume: 89 start-page: 669 issue: 1 year: 2015 ident: 2021110300462725700_CIT0015 article-title: Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines publication-title: J Virol. doi: 10.1128/JVI.02184-14 contributor: fullname: Crosby – start-page: 2348 issue: 48 year: 2011 ident: 2021110300462725700_CIT0017 article-title: Isolation of brain and spinal cord mononuclear cells using percoll gradients publication-title: J Vis Exp contributor: fullname: Pino – volume: 23 start-page: 239 issue: 1 year: 2017 ident: 2021110300462725700_CIT0029 article-title: The Efficacy of Oncolytic Adenovirus Is Mediated by T-cell Responses against Virus and Tumor in Syrian Hamster Model publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-16-0477 contributor: fullname: Li – volume: 9 start-page: e97495 issue: 5 year: 2014 ident: 2021110300462725700_CIT0030 article-title: The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity publication-title: PLoS One. doi: 10.1371/journal.pone.0097495 contributor: fullname: Kleijn – volume: 99 start-page: 1410 issue: 18 year: 2007 ident: 2021110300462725700_CIT0007 article-title: Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/djm102 contributor: fullname: Jiang – volume: 95 start-page: 652 issue: 9 year: 2003 ident: 2021110300462725700_CIT0004 article-title: Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway publication-title: J Natl Cancer Inst. doi: 10.1093/jnci/95.9.652 contributor: fullname: Fueyo – volume: 9 start-page: e97407 issue: 5 year: 2014 ident: 2021110300462725700_CIT0008 article-title: Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model publication-title: PLoS One. doi: 10.1371/journal.pone.0097407 contributor: fullname: Jiang – volume: 432 start-page: 396 issue: 7015 year: 2004 ident: 2021110300462725700_CIT0021 article-title: Identification of human brain tumour initiating cells publication-title: Nature. doi: 10.1038/nature03128 contributor: fullname: Singh – volume: 36 issue: 14 year: 2018 ident: 2021110300462725700_CIT0005 article-title: Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma publication-title: J Clin Oncol doi: 10.1200/JCO.2017.75.8219 contributor: fullname: Lang – volume: 115 start-page: 69 year: 2012 ident: 2021110300462725700_CIT0023 article-title: Chapter three–Syrian hamster as an animal model to study oncolytic adenoviruses and to evaluate the efficacy of antiviral compounds publication-title: Adv Cancer Res. doi: 10.1016/B978-0-12-398342-8.00003-3 contributor: fullname: Wold – volume: 379 start-page: 150 issue: 2 year: 2018 ident: 2021110300462725700_CIT0001 article-title: Recurrent glioblastoma treated with recombinant poliovirus publication-title: N Engl J Med. doi: 10.1056/NEJMoa1716435 contributor: fullname: Desjardins – volume: 18 start-page: 1137 issue: 8 year: 2016 ident: 2021110300462725700_CIT0003 article-title: Phase II multicenter study of gene-mediated cytotoxic immunotherapy as adjuvant to surgical resection for newly diagnosed malignant glioma publication-title: Neuro Oncol. doi: 10.1093/neuonc/now002 contributor: fullname: Wheeler – volume: 66 start-page: 1270 issue: 3 year: 2006 ident: 2021110300462725700_CIT0013 article-title: Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors publication-title: Cancer Res. doi: 10.1158/0008-5472.CAN-05-3497 contributor: fullname: Thomas – volume: 14 start-page: 339 issue: 4 year: 1989 ident: 2021110300462725700_CIT0009 article-title: Restricted replication of human adenovirus type 5 in mouse cell lines publication-title: Virus Res. doi: 10.1016/0168-1702(89)90026-9 contributor: fullname: Blair – volume: 21 start-page: 171 issue: 4 year: 2014 ident: 2021110300462725700_CIT0027 article-title: Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamsters publication-title: Cancer Gene Ther. doi: 10.1038/cgt.2014.13 contributor: fullname: Dhar – volume: 16 start-page: 1665 issue: 10 year: 2008 ident: 2021110300462725700_CIT0028 article-title: Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model publication-title: Mol Ther. doi: 10.1038/mt.2008.162 contributor: fullname: Thomas – volume: 155 start-page: 462 issue: 2 year: 2013 ident: 2021110300462725700_CIT0019 article-title: The somatic genomic landscape of glioblastoma publication-title: Cell. doi: 10.1016/j.cell.2013.09.034 contributor: fullname: Brennan – volume: 110 start-page: 6021 issue: 15 year: 2013 ident: 2021110300462725700_CIT0020 article-title: TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal publication-title: Proc Natl Acad Sci U S A. doi: 10.1073/pnas.1303607110 contributor: fullname: Killela – volume: 16 start-page: 625 issue: 8 year: 2009 ident: 2021110300462725700_CIT0010 article-title: INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies publication-title: Cancer Gene Ther. doi: 10.1038/cgt.2009.6 contributor: fullname: Ying |
SSID | ssj0021561 |
Score | 2.4143467 |
Snippet | Abstract
Background
Oncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are... BACKGROUNDOncolytic adenoviruses are promising new treatments against solid tumors, particularly for glioblastoma (GBM), and preclinical models are required to... |
SourceID | pubmedcentral proquest crossref oup |
SourceType | Open Access Repository Aggregation Database Publisher |
StartPage | 1911 |
SubjectTerms | Basic and Translational Investigations |
Title | An immune-competent, replication-permissive Syrian Hamster glioma model for evaluating Delta-24-RGD oncolytic adenovirus |
URI | https://search.proquest.com/docview/2535827747 https://pubmed.ncbi.nlm.nih.gov/PMC8563315 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB61PVS9IJ5ioVQGIXEhTWLHdnKsWsoCKkJApd4i27FLpF1ntZut6L9nnMeKnJA45yFnZuJ8k_nmG4C3zjAqteARE6rCBEXjK-V4FbGcc2YlD5NRAtviq5hfZ59v-M0e8LEXpiPtG12f-sXy1Ne_Om7lamnikScWf7s6z7lgLOXxPuxLxsYUfciyMCHpRVIxywqD53dKjSz2dtt4E_tGadyWj-CQZUGehKaTj9Kk0S3gzSlb8q_Pz-VDeDDgRnLWr-8R7Fn_GA6vhsr4E_h95kkdej1sZAYo3L4na7srT0erQHvZBLY6-XGPYefJXC2DTAK5XdTNUpFuKA5BEEtGCXB_Sy7solURzaLvHy8IPlazuMcVEIXbVXNXr7ebp3B9-eHn-TwapipEBnOpNlD3pZQszVSSuqKba5sII7WjTpuiMnngm1aVSIzLEzQUs5W0hWUis3nh0IzP4MA33j4HwpgI8KkwiLoyp5y2NBeOaeqsSVTKZ_BuNGu56sUzyr7ozcreF-Xgixm8Qav_86TXo1NKNFiobChvm-2mpDw0_CKSlTOQE2_tbhlktKdHMLo6Oe0hml7895Uv4YgGpkv42UyP4aBdb-0rhCqtPkGQ_unLSRegfwCx-u3P |
link.rule.ids | 230,315,733,786,790,891,27955,27956,53825,53827 |
linkProvider | National Library of Medicine |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL0qRSrd8K6Y8jIIiQ2ZJHacZJZVSxmgUyFoUXeR7dgl6owzmkkQ5eu5zmNE2CBY5yHHx49z43PPBXhlFKOJjLnHYpFjgCJxShmeeyzlnOmEu8ooTm1xGk_Pow8X_GILeJ8L04j2lSzGdr4Y2-Jbo61cLpTf68T8T7PDlMeMhdy_ATdxvlLeB-ldnIUhSWuTinGWKz2_8WpkvtV1aZVvSyFxYd6FHRY5gxIaDralQaqbY5xDveRvG9DxHfjaN73VnVyN60qO1c8_XB3_-dvuwu2OkpKD9vI92NL2PuzMukP3B_DjwJLCpZFoT3Usu3pDVnpz8u0tnaJm7YTw5Ms1jmhLpmLhHBjI5bwoF4I09XYI8mPSu4vbS3Kk55XwaOR9fndEsL_K-TW2gAhcCcvvxapeP4Tz47dnh1OvK9jgKQzTKpcVkCQJCyMRhGbSlMwNYpVIQ41Uk1ylTsqa53GgTBogAkzniZ5oFkc6nRjEZw-2bWn1IyCMxY6ZTRQSusgIIzVNY8MkNVoFIuQjeN3jlS1bX46sPU9nWQty1oE8gpcI519vetGjnWGHuUMTYXVZrzPKXS4xkuRkBMlgGGxe6Ry6h1cQ3MapuwNz_7-ffA63pmezk-zk_enHx7BLnaDG_dOmT2C7WtX6KTKiSj5rxv8vTVgO2g |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLVgSNVeYNy0AhsGIfFCmsSO4-RxWinlsmkCJk28RLZjj4jWqdoEMX79PudSLbwg7TlO5OT4cr58x-dD6I1RlHAZM4_GIocARcKUMiz3aMIY1Zy5yihObXEaz8-jTxfs4kapr0a0r2QxsYvlxBY_G23laqn8Xifmn50cJyymNGT-Kjf-XXQP5izhfaDexVoQlrRWqRBrufLzW79G6ltdl1b5thQSFuddNKKRMykh4WBrGhx3c6xzqJm8sQnNHqAfffdb7cmvSV3Jifr7j7Pjrd5vD93vqCk-aps8RHe0fYRGJ13y_TH6c2Rx4Y6TaE91bLt6h9d6mwH3Vk5Zs3GCePztCka2xXOxdE4M-HJRlEuBm7o7GHgy7l3G7SWe6kUlPBJ5Xz9MMXyzcnEFPcACVsTyd7GuN0_Q-ez99-O51xVu8BSEa5U7HcA5p2EkgtCkTencIFZcGmKkSnOVOElrnseBMkkAKFCdc51qGkc6SQ1g9BTt2NLqfYQpjR1DSxUQu8gIIzVJYkMlMVoFImRj9LbHLFu1_hxZm1enWQt01gE9Rq8B0v82etUjnsEHc8kTYXVZbzLC3JliIMt8jPhgKGwf6Zy6h1cA4MaxuwP02a3vfIlGZ9NZ9uXj6efnaJc4XY37tU1eoJ1qXesDIEaVPGymwDWrThFa |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=An+immune-competent%2C+replication-permissive+Syrian+Hamster+glioma+model+for+evaluating+Delta-24-RGD+oncolytic+adenovirus&rft.jtitle=Neuro-oncology+%28Charlottesville%2C+Va.%29&rft.au=Phillips%2C+Lynette+M&rft.au=Li%2C+Shoudong&rft.au=Gumin%2C+Joy&rft.au=Daou%2C+Marc&rft.date=2021-11-02&rft.pub=Oxford+University+Press&rft.issn=1522-8517&rft.eissn=1523-5866&rft.volume=23&rft.issue=11&rft.spage=1911&rft.epage=1921&rft_id=info:doi/10.1093%2Fneuonc%2Fnoab128&rft.externalDocID=10.1093%2Fneuonc%2Fnoab128 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1522-8517&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1522-8517&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1522-8517&client=summon |